Anti-tumour necrosis factor therapy in seronegative spondyloarthritis.
Over 50% of ankylosing spondylitis patients treated with anti-tumour necrosis factor show a 50% improvement Infliximab, etanercept (and probably adalimumab) are equally effective Stable responses are maintained for two years If treatment is discontinued, almost all patients relapse Retreatment is pr...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2005
|